794564-44-6

Usage

Uses

Used in Pharmaceutical Industry:
3-(2,3-Dihydro-1,4-benzodioxin-6-yl)-1-[4-ethyl-2-(β-D-glucopyranosyloxy)-6-hydroxyphenyl]-1-propanone is used as a selective SGLT2 inhibitor for the treatment of type 2 diabetes. Its ability to inhibit SGLT2 leads to reduced glucose reabsorption in the kidneys, resulting in lowered blood glucose levels and improved glycemic control.
Used in Drug Development:
3-(2,3-Dihydro-1,4-benzodioxin-6-yl)-1-[4-ethyl-2-(β-D-glucopyranosyloxy)-6-hydroxyphenyl]-1-propanone is also used in the development of new drugs targeting SGLT2 for the management of type 2 diabetes and related complications. Its potent and selective action on SGLT2 makes it a promising candidate for the development of innovative therapeutic agents.
Used in Research:
3-(2,3-Dihydro-1,4-benzodioxin-6-yl)-1-[4-ethyl-2-(β-D-glucopyranosyloxy)-6-hydroxyphenyl]-1-propanone is utilized in research studies to investigate the role of SGLT2 in glucose homeostasis and its potential as a therapeutic target for diabetes management. Its unique structure and properties make it a valuable tool for understanding the mechanisms of SGLT2 inhibition and its effects on glucose metabolism.

Upstream product

• 572-09-8 2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl bromide 
• 209746-97-4 4'-ethyl-2',6'-dihydroxyacetophenone 2'-O-(2,3,4,6-O-tetraacetyl)-β-D-glucopyranoside 
• 209746-96-3 4'-ethyl-2',6'-dihydroxyacetophenone 
• 4299-72-3 5-ethylresorcinol 

Relevant academic research and scientific papers

Glycosylated dihydrochalcones as potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitors

A series of glucose conjugates was synthesized and tested for inhibition of SGLT1 and SGLT2.